New study shows CT-measured body fat, not BMI, links obesity to higher lung cancer risk via immune T-cell changes—hinting at prevention through weight loss.
|Videos|November 28, 2018
Selecting Cytoreductive Therapy for Patients with PV or ET
Author(s)Laura Michaelis, MD
Laura Michaelis, MD, discusses how to select patients with either polycythemia vera or essential thrombocythemia for cytoreductive therapy.
Advertisement
Laura Michaelis, MD, associate professor of medicine, Medical College of Wisconsin, discusses how to select patients with either polycythemia vera (PV) or essential thrombocythemia (ET) for cytoreductive therapy.
According to Michaelis, if a patient with PV is over the age of 60 or has had a prior arterial or venous clot, she will give these patients cytoreductive treatment. However, she does not treat patients with ET the same way.
Advertisement
Related to this article
The IMpactMF trial was discontinued after an independent committee determined imetelstat was unlikely to improve overall survival.
The phase 3 VERIFY trial found that rusfertide improved clinical response, reduced phlebotomy requirements, and eased symptom burden in patients with polycythemia vera receiving standard-of-care therapy.
At Rutgers Cancer Institute, neuro-oncologists met to discuss the latest trends in precision brain cancer care with FET-PET imaging, advanced molecular testing, and same-day multidisciplinary clinics.
Advertisement
Advertisement
Trending on Targeted Onc
1
ESMO 2026: ADCs and New Combinations Advance Lung Cancer Care
2
Novel ADCs Show Responses in Ovarian and Cervical Cancer at ESMO 2026
3
340B Contract Pharmacy Case Rekindles Scrutiny Over Program Intent
4
ESMO 2026: New Data Advance Prostate, Kidney, and Bladder Cancer Care
5